Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanicemine

Next Previous
Drug Profile

Lanicemine

Alternative Names: ARL 15896; ARL 15896AR; ARR 15896; ARR 15896AR; BHV-5500; FPL 15896; FPL 15896AR

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astra Arcus USA
  • Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Epilepsy; Stroke

Most Recent Events

  • 31 May 2017 Baylor College of Medicine and National Institute of Mental Health plan a phase I trial for Depression and Post traumatic stress disorders (NCT03166501)
  • 23 Jan 2007 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 17 Feb 2006 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top